Meeting

State-of-the-Art Clinical Symposium

Date:

May 16 - 17, 2020

Location:

ACR Beyond LIVE

Program Information

CME: 10.0*    MOC: 10.0*

*Subject to change

The in-person portion of the 2020 State-of-the-Art Clinical Symposium has been canceled and will be held virtually via ACR Beyond LIVE.

Speakers will deliver a range of high-impact content in areas such as therapeutic developments, recent research findings, and scientific advances. There will also be a 10-minute virtual Q&A with speakers following selected sessions, as well as additional opportunities to interact with other virtual attendees. Attendees can also visit the virtual Exhibit Hall, with the opportunity to win prizes for visiting booths.

Attendees will have access to the ACR Beyond platform two weeks before the event (accessible in My Educational Activities), where they will be able to explore on-demand ACR content as well as complete the premeeting survey. Access to ACR Beyond will be available for 90 days after the event concludes.

Note: The FIT Program and E/M Documentation Course pre-symposium activities will not be held virtually.

Program Schedule

Coming soon

Registration Fees

ACR/ARP Member
Member - $220
Resident/Student - $95
Master/Emeritus - $115
Fellow in Training - $0

Nonmember
Nonmember - $325
Resident/Student - $155*
Fellow in Training - $0

*If you are a nonmember resident or student who is pursuing a medical, undergraduate or graduate degree, or a nonmember fellow in training, to request the reduced registration fee please send a letter from your program director or chief of service to education@rheumatology.org.

Syllabi

Program syllabi will be available online during the meeting and for 12 months after the meeting to registered attendees only. To access syllabi, login and go to My Educational Activities.

CME and MOC Information

Accreditation Statement
The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement
The ACR designates this live activity for a maximum of 10.0* AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activities. Participants can claim the following:

  • 10.0* AMA PRA Category 1 Credit(s)™ for attending the State-of-the-Art Clinical Symposium

MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.0* MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

*Subject to change

Faculty and Disclosures

Updated faculty information coming soon

ACR Disclosure Statement
The ACR is an independent, professional organization that does not endorse specific procedures or products of any pharmaceutical/biotech concern. Educational activities provided by the ACR must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias.

Faculty participating in an ACR-sponsored activity must disclose to the planning committee and audience any financial or other relationship(s) including, but not limited to:

  1. Stock, stock options or bond holdings in a for-profit corporation or self-directed pension plan
  2. Research grants
  3. Employment (full or part-time)
  4. Ownership or partnership
  5. Consulting fees or other remuneration (payment)
  6. Non-remunerative positions of influence such as officer, board member, trustee, or public spokesperson
  7. Receipt of royalties
  8. Speakers' bureau
  9. Other

The planning committee and faculty reported the following disclosures.

State-of-the-Art Clinical Symposium Planning Committee

  • Meenakshi Jolly, MD, MS - Rush University7, Pfizer2
  • Narender Annapureddy, MD, MS - No relevant financial relationships to disclose
  • Francesco Boin, MD - No relevant financial relationships to disclose
  • Liana Fraenkel, MD, MPH - No relevant financial relationships to disclose
  • Lianne Gensler, MD – Novartis2, Pfizer2, UCB2, Abbvie5, Galapagos5, Janssen5
  • Manjari Malkani, MD - No relevant financial relationships to disclose
  • Rebecca Manno, MD - Sanofi5, Novartis2, Paradigm Education5
  • Michael Putman, MD - No relevant financial relationships to disclose

State-of-the-Art Clinical Symposium Faculty

  • Francesco Boin, MD - No relevant financial relationships to disclose
  • Eliza F. Chakravarty, MD - No relevant financial relationships to disclose
  • Erika Darrah, PhD - No relevant financial relationships to disclose
  • Kevin Deane, MD, PhD - BMS5, Inova Diagnostics Inc.5, 2, Janssen2, Microdrop, Inc.5, ThermoFisher Scientific 5
  • Tracy Frech, MD - No relevant financial relationships to disclose
  • Marvin Fritzler, MD, PhD - Aesku5, Alexion Canada: Diagnostic test support2, 9, 8, Euroimmun GmbH9, Inova Diagnostics Inc. 5, 8, Werfen Inernational5, 8
  • Jon Giles, MD, MPH - AbbVie 5; Bristol Myers Squibb Co., Ltd. 5; Eli Lilly and Co. 5, Pfizer2, Roche/Genentech5, UCB Pharma5
  • Nigil Haroon, MD, PhD, DM, FRCPC - AbbVie5, Amgen8, Eli Lilly8, Janssen5, Novartis5, Novo Nordisk8, UCB5
  • Laura Hummers, MD - Boehringer Ingelheim5, 2, Corbus Pharmaceuticals2 CSL Behring5, 2 Cumberland2, EICOS2, Glaxo Smith Kline2, Kadmon2
  • Tanaz Kermani, MD - Genentech5, 9
  • Walter Maksymowych, MD, FRCPC - AbbVie, Boehringer Ingelheim, CARE Arthritis, Celgene, Ely Lilly, Galapagos, Janssen, Novartis, Pfizer, UCB, CARE Arthritis 5, 2, 9, 8
  • Joan Merrill, MD - Abbvie5, 8, Amgen5, Astellas5, Astra Zeneca5, Bristol Myers Squibb Co. Ltd. 5, 2, Celgene5, Daiichi Sankyo5, EMD Serono5, Glaxo Smith Kline5, 2, ILTOO5, Immupharma5, Incyte5, Janssen5, Lilly5, Remegen5, Servier5, Zencor2
  • Tuhina Neogi, MD, PhD, FRCPC - EMD Merck Serono5, Novartis5, Pfizer5
  • James T. Rosenbaum, MD - AbbVie5
  • Deborah Sellmeyer, MD - No relevant financial relationships to disclose
  • Ami Shah, MD - No relevant financial relationships to disclose

Corporate Support

The American College of Rheumatology thanks our corporate supporters and partners for their commitment to advancing rheumatology by supporting ACR and ARP programs and initiatives. See current supporters, guidelines, and benefits of supporting the ACR.

Press Registration

Coming soon

Contact Info / Inquiries

American College of Rheumatology
education@rheumatology.org
404-633-3777, ext. 381

© 2020 American College of Rheumatology.  All rights reserved.  Website & Privacy Policies | Sitemap | Help | Contact Us